Clinical significance of the Lacdi NA c‐glycosylated prostate‐specific antigen assay for prostate cancer detection

Autor: Takatoshi Kaya, Kazuyuki Mori, Tohru Yoneyama, Yoshihiko Suda, Tomonori Kaneko, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Yuki Tobisawa, Chikara Ohyama, Wilhelmina C.M. Duivenvoorden, Shingo Hatakeyama, Koji Mitsuzuka, Takuya Koie, Robert A. Gardiner, Teppei Okubo, Mihoko Sutoh Yoneyama, Akihiro Ito
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Glycosylation
medicine.medical_treatment
Lactose
clinically significant prostate cancer
urologic and male genital diseases
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Clinical Research
Prostate
Internal medicine
Biopsy
Humans
Medicine
Clinical significance
Aged
Retrospective Studies
N‐glycan
medicine.diagnostic_test
Receiver operating characteristic
business.industry
Prostatectomy
Prostatic Neoplasms
Original Articles
General Medicine
Middle Aged
Prostate-Specific Antigen
medicine.disease
LacdiNAc
Tumor Burden
Prostate-specific antigen
030104 developmental biology
medicine.anatomical_structure
ROC Curve
030220 oncology & carcinogenesis
Cohort
biomarker
Original Article
prostate‐specific antigen
Neoplasm Grading
business
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
DOI: 10.1111/cas.14082
Popis: To reduce unnecessary prostate biopsies (Pbx), better discrimination is needed. To identify clinically significant prostate cancer (CSPC) we determined the performance of LacdiNAc‐glycosylated prostate‐specific antigen (LDN‐PSA) and LDN‐PSA normalized by prostate volume (LDN‐PSAD). We retrospectively measured LDN‐PSA, total PSA (tPSA), and free PSA/tPSA (F/T PSA) values in 718 men who underwent a Pbx in 3 academic urology clinics in Japan and Canada (Pbx cohort) and in 174 PC patients who subsequently underwent radical prostatectomy in Australia (preop‐PSA cohort). The assays were evaluated using the area under the receiver operating characteristics curve (AUC) and decision curve analyses to discriminate CSPC. In the Pbx cohort, LDN‐PSAD (AUC 0.860) provided significantly better clinical performance for discriminating CSPC compared with LDN‐PSA (AUC 0.827, P = 0.0024), PSAD (AUC 0.809, P
Databáze: OpenAIRE
Externí odkaz: